[Rational use of catecholamines and inotropes].

Area of Science:

• Cardiology
• Pharmacology

Background:

• Acute heart failure syndromes (AHFS) are increasingly prevalent in Western countries.
• Patients with AHFS and low cardiac output present unique therapeutic challenges, marked by high mortality rates.
• Current treatments often require intravenous inotropic support.

Purpose of the Study:

• To review existing inotropic agents used for AHFS.
• To introduce novel drug developments for AHFS treatment.
• To address the therapeutic challenges in AHFS with low cardiac output.

Main Methods:

• Literature review of current inotropic therapies.
• Discussion of established drug classes: adrenoreceptor agonists, phosphodiesterase III inhibitors, and Ca2+ sensitizers.
• Exploration of emerging drug targets, including myosin activators and Na+/K+ ATPase inhibitors.

Main Results:

• Current inotropes offer short-term hemodynamic benefits but are linked to increased myocardial oxygen consumption and arrhythmias.
• Existing treatments may be associated with higher post-discharge mortality.
• Newer agents like myosin activators and Na+/K+ ATPase inhibitors represent potential advancements.

Conclusions:

• The management of AHFS, particularly in low cardiac output states, requires careful consideration of inotropic therapy risks and benefits.
• Existing inotropes have limitations, including adverse effects and potential impact on long-term survival.
• Novel therapeutic strategies are under development to improve outcomes for patients with AHFS.